390 related articles for article (PubMed ID: 15930019)
1. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG imaging: pitfalls and artifacts.
Abouzied MM; Crawford ES; Nabi HA
J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
[TBL] [Abstract][Full Text] [Related]
3. PET scan in lung cancer: current recommendations and innovation.
Vansteenkiste JF; Stroobants SS
J Thorac Oncol; 2006 Jan; 1(1):71-3. PubMed ID: 17409830
[TBL] [Abstract][Full Text] [Related]
4. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
6. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
7. Value of whole-body FDG PET in management of lung cancer.
Higashi K; Matsunari I; Ueda Y; Ikeda R; Guo J; Oguchi M; Tonami H; Yamamoto I
Ann Nucl Med; 2003 Feb; 17(1):1-14. PubMed ID: 12691125
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
9. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies.
O JH; Yoo IeR; Kim SH; Sohn HS; Chung SK
J Nucl Med; 2007 Jan; 48(1):15-21. PubMed ID: 17204694
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for Lung Cancer Staging.
Ohno Y; Koyama H; Lee HY; Yoshikawa T; Sugimura K
J Thorac Imaging; 2016 Jul; 31(4):215-27. PubMed ID: 27075745
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-Art FDG-PET imaging of lung cancer.
Gilman MD; Aquino SL
Semin Roentgenol; 2005 Apr; 40(2):143-53. PubMed ID: 15898411
[TBL] [Abstract][Full Text] [Related]
13. Routine use of dual time ¹⁸F-FDG PET for staging of preoperative lung cancer: does it affect clinical management?
Shinozaki T; Utano K; Fujii H; Utano Y; Sasaki T; Kijima S; Kanazawa H; Kimura Y; Fujita A; Sugimoto H
Jpn J Radiol; 2014 Aug; 32(8):476-81. PubMed ID: 24866251
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
15. Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
Vesselle H; Turcotte E; Wiens L; Haynor D
J Nucl Med; 2003 Dec; 44(12):1918-26. PubMed ID: 14660717
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.
Chung JH; Cho KJ; Lee SS; Baek HJ; Park JH; Cheon GJ; Choi CW; Lim SM
J Nucl Med; 2004 Jun; 45(6):999-1003. PubMed ID: 15181136
[TBL] [Abstract][Full Text] [Related]
17. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
20. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies.
Kamel EM; McKee TA; Calcagni ML; Schmidt S; Markl S; Castaldo S; Delaloye AB
Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):641-6. PubMed ID: 15726357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
